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Abstract
This work will, in addition to describing the aromatic basis of capsaicin, elucidate its
mechanism of action through a positive inhibition of the nerve conduction,  which
ultimately accounts for the various pharmacological effects of capsaicin on pain control,
cardiovascular mechanisms, as well as its effects on genitourinary and gastrointestinal
tracts.
Keywords: capsaicin, aromatics, desensitization, mechanism of action, positive inhibi‐
tion
1. Introduction
The current study is a systemic review of the pharmacology and chemistry of capsaicin and
capsaicinoids. The genus Capsicum is a member of the Solanaceae family that includes tomato,
potato, tobacco, and petunia. The genus Capsicum consists of approximately 22 wild species
and 5 domesticated species [1] including C. annuum, C. baccatum, C. chinense, C. frutescens, and
C. pubescens.
Capsicum species have been used as medicinal plants to treat intestinal upsets and indigestion
and also as stimulants, rubefacient, and tonic. They have also been used as folk remedies for
dropsy, colic, diarrhea, asthma, arthritis, muscle cramps, and toothache. In addition, Capsicum
frutescens L. has been reported to have hypoglycemic properties [2]. However, prolonged
contact with the skin may cause dermatitis and blisters, while excessive consumption can cause
gastroenteritis and/or kidney damage. Besides, paprika and cayenne pepper may be cytotoxic
to mammalian cells, in vitro. Moreover, consumption of red pepper may aggravate symptoms
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of duodenal ulcers. It has also been shown that high levels of ground hot pepper have induced
stomach ulcers and cirrhosis of the liver in laboratory animals. As a stimulant Capsicum species
could stimulate body temperature, salivation, and increase gastric juices.
This study was undertaken to investigate the anti‐inflammatory property of Capsicum
frutescens ethyl acetate extract (CFE) and capsaicin (CPF) in rat model to provide a pharma‐
cological rationale for the folklore medicine uses of capsaicin and capsaicinoids to treat
arthritis, muscle sprain, and other inflammatory conditions in some communities. One of the
main objectives of this study was to determine if Capsicum frutescens fruit extract in this study
has similar efficacy on peripheral and central components of pain as so described for Capsicum
spp. (Linn) [Solanaceae] from other parts of the world, such as from India, Mexico, Thailand,
and South America [3].
2. Research methods
Following Ethics approval by the Animal Ethics Committee of the University of KwaZulu—
Natal; Westville Campus, various parallel and comparative studies were carried out on crude
extract ethyl acetate of Capsicum frutescens and synthetic capsaicin. The studies were to
elucidate the analgesic, antiinflammatory, gastro‐intestinal effects and the effects on coagula‐
tion of both compounds. The discussion that follows is a systemic review of the pharmaco‐
logical effects of capsaicin. The “hot plate” and “acetic acid” analgesic tests methods were used
for central and peripheral nervous system investigations on pain mechanisms, using the mean
reaction time and inhibition of writhing, respectively. The effects of Capsicum‐derived capsaicin
on chick isolated parasympathetically innervated esophagus, rabbit duodenum, and guinea
pig ileum were investigated in Ugo Basile organ baths, respectively. In all cases, concentration‐
response curves to standard agonists were investigated in the absence and in the presence of
capsaicin (CPE), or standard antagonists. Following 2 weeks of treatment with capsaicin and
capsicum extracts, the effects of capsaicin on coagulation was tested. The results of these
studies show comparable analgesic to morphine and diclofenac on the peripheral analgesic
mechanisms and more intense central analgesia compared to morphine (p < 0.1). Besides,
capsaicin increased the INR by 1.25 times compared to control (p < 0.01) and has a dose‐
dependent relaxation of the gastro‐intestinal smooth muscles (p < 0.1).
3. Data analysis
Experimental data obtained were analyzed and presented as means (+SEM). The data from
“control” rats were used as baseline values while the mean reaction times to the pain stimulus
or the writhing were recorded and subsequently analyzed, using a two‐way ANOVA.
Interobserver differences were assessed by Wilcoxon and Kruskal‐Wallis tests. Student's t‐test
was used to test for the difference between the means when two groups were analyzed. Where
the groups are more than two, ANOVA was used to test for differences between the groups.
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Statistical significance was by using a double‐tailed CI of 95% and a p‐value of less than 0.05.
Pearson correlation coefficient was used to assess the activity of Capsicum frutescens–derived
capsaicin extract, compared to that of the synthetic capsaicin and to compare results from
selected groups.
4. Discussion
Capsicum species occur worldwide, and has been used for more than 9000 years by the Chinese,
Indians, and Africans for medicinal and nonmedicinal purposes [4], for example, for pain,
among other things. Pain is perceived through both peripheral and central mechanisms.
Peripheral mechanisms typically involve the nociceptors, while central mechanisms involve
the process of central sensitization. Pain is sensed by nociceptors located in the sensory nerve
endings. Messages are relayed through complex multisynaptic afferents to the dorsal column
by means of transmission and transduction of chemical messages, which are relayed via the
spinal mechanisms and processed for appropriate supranuclear interpretation. Finally, the
motor effector organs are facilitated to respond according to the type of pain [5, 6].
The neural impulses, which originate from the nociceptors, relay through the primary afferent
nerves (PAN), to the spinal cord, or via the cranial nerves to the brain stem, for those impulses
that originate from the head and neck. The cell bodies of these ganglia are located in the dorsal
root ganglia, or the respective cell bodies in the cases of cranial nerves V, VIII, IX, and X. By
means of complex synapses, messages are relayed to ascending pathways.
There are several biochemical mediators (and neurotransmitters), which are involved in pain
transmission and perception. Peripherally, the most important of these amines are the cyclo‐
oxygenase agonists and the leukotrienes. Others are catecholamines, acetylcholine, vasoactive
intestinal polypeptides (VIP), neuropeptides Y (NPY), cholecystokinin, 5‐hydroxytryptamine,
neurotensin, tachykinin, and bradykinins [7, 8]. The opioid receptors act both centrally and
peripherally. In addition, the central cyclo‐oxygenase action has been found with acetamino‐
phen [9]. Centrally acting neuromediators can be classified into “excitatory” and “inhibitory”
neuromediators. Glutamate and aspartate are the examples of excitatory amino acids acting
as neurotransmitters centrally, while substance P (SP), calcitonin gene‐related peptide (CGRP)
[10], and growth factors (e.g., brain‐derived neurotrophic factors) are other examples. Inhibi‐
tory neuromediators include endogenous opioids, such as enkephalin and β‐endorphins.
Others are gamma‐aminobutyric acid (GABA), glycine, and β‐adrenergic agonists [11].
Conversely, any agent acting on these receptors and neuromediators have the ability to
modulate pain. The aberration of inflammatory and neuropathic enhancement of pain
perception as seen in allodynia (painful touch) and hyperalgesia are due to increased release
of SP from substantia gelatinosa. This phenomenon is called “peripheral sensitization.”
The memory of pain, neural plasticity, wide dynamic range activity, and the winding
phenomenon are enhanced by N‐methyl‐d‐aspartate receptor through an early expression
of genetic coding through c‐fos and v‐fos oncogens [12–15]. This neural plasticity leads to
the phenomenon of central sensitization as typified by stump and phantom pain. Both
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hyperalgesia and allodynia, which are known side effects of capsaicin [16], are results of
peripheral and central sensitization. In addition, the repetitive C fiber stimulation produces
the winding‐up phenomenon.
Injury leads to nociception, transduction, receptor modification, uncoordinated sprouting, and
growth of injured axons and ectopic epileptic firing of nerves [17]. Although the hypothalamus
receives an enormous amount of stimuli, it is devoid of the ability to discriminate, since it is
not somato‐topically organized. It is also not able to localize pain. However, discrimination
and localization are possible by the third‐order neurons connecting to the prefrontal gyrus in
the cerebral cortex. This is the basis for the use of secondary analgesia such as antidepressants
and anticonvulsants.
The ascending order is not alone in pain modulation. There is enough evidence to suggest that
the descending tracts have a role in the modulation of pain [18]. In the late 1960s, it was
observed that neurons in the dorsal horn of decerebrated animals are more responsive to
painful stimuli when the spinal cord is blocked [19]. Also in the late 1980s, electrical stimulation
of the periaqueductal gyrus was found to produce profound relief of pain in animals [17].
These studies provided scientific basis for stimulation‐produced analgesia. In addition, further
studies showed that instillation of small doses of morphine in the regions such as periaque‐
ductal system (PAG) produced significant analgesia.
Substance P is the active neurotransmitter that is released at the primary nerve endings of
primary afferent neurons (PAN). It is usually synthesized at the substantia gelatinosa of the
dorsal horn. On release from PAN, substance P from the dorsal horn of the spinal cord exhibits
systemic actions. For example, the expression of substance P and vanilloid receptor (VR1) were
found in the trigeminal sensory neurons projecting from PAN to the nasal mucosa in the
mouse [20, 21]. The release of both substance P and neurokinin A (NKA) from PAN to various
stimuli induced by capsaicin (vanilloid) receptor (VR1) results in potent proinflammatory
effects on the airways [22, 23].
Expression of substance P was found to correlate with the severity of diarrhea in cryptospor‐
idosis from the result in electrogenic chloride anion secretion [24,25] and found three kinds of
current in response to substance P in bullfrog dorsal root ganglion neurons. They are either
G‐protein coupled channel, slow activating I (SP); or directly opened channel, fast activating
I (SP); or both, moderately activating I (SP). All the three were inwardly directed currents with
the ionic mechanism underlying slow activating I (SP) deduced as closure of K+ channels. The
fast‐activating channel is due to the opening of sodium channels. These correlate with the three
subtypes of SP receptor, immunoreactive interneurons described in the rat basolateral
amygdala [26]. Furthermore, the secretion of HCO‐3 through secretin was abolished by
substance P [15, 24, 27].
Other systems affected by substance P include the cardiovascular system. Low dose systemic
administration of substance P caused hypertension and tachycardia, while unilateral or
bilateral injections into the rat's nucleus tractus solitari caused slow increase in blood pressure
and heart rate, which peaked in 1.5–5 min after injection and lasted for 20–30 min. These effects
are vagal mediated [28, 29].
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Furthermore, the swellings that typically accompany complex regional pain syndrome have
been found to be due to extravasation of substance P–induced protein [24, 30].
Capsaicin is the main pungent ingredient in “hot” chili peppers, and elicits a burning pain by
selectively activating sensory neurons that convey information about noxious stimuli to the
central nervous system [31, 32]. However, capsaicin‐induced ion refluxes increase cyclic GMP
and not cyclic AMP [33], capsaicin has selective action on unmyelinated C‐fibers and thinly
myelinated A primary sensory neurons [33].
Several sensory stimuli including noxious pressure, heat, and chemical irritation could affect
capsaicin‐sensitive fibers, which are polymodal in nature. These nociceptors are the most
abundant class of nociceptive fibers. On stimulation by capsaicin, nociceptive neurons release
glutamate, which are a rapidly acting central neurotransmitter and an excitatory amino acid.
Likewise, the transient receptor potential (TRP) family of ion channels are activated by a
diverse range of stimuli, including heat, protons, lipids, phorbols, phosphorylation, changes
in extracellular osmolarity and/or pressure, and depletion of intracellular Ca2+ stores. In all,
VR 1 remains the only channel activated by vanilloids such as capsaicin [34].
In addition, they also express neuropeptides, such as calcitonin‐gene‐related‐peptide (CGRP),
substance P, nerokinin A, and somatostantin, which, on release to the spinal cord, leads to
intense stimulation. Noxious stimulation acting on peripheral nervous system results in a long‐
term increase in spinal excitability, which results in the central mechanisms of allodynia and
hyperalgesia. There is neuronal cooperation and enhancement of activities by tachykinins (e.g.,
substance P and neurokinin A) and excitatory amino acids (EAAs) (e.g., glutamate), which
ultimately increase synaptic activation of dorsal horn neurons via EAA receptors. Following
synthesis at the dorsal root ganglia, most of the neuropeptides are exported peripherally and
not centrally, to facilitate neurogenic inflammation. Capsaicin pretreatment in neonatal rats
has been found to abolish the development of thermal hyperalgesia produced in a model of
neuropathic pain in rats [35, 36].
An initial local application of capsaicin is algesic. However, its repeated application leads to
desensitization, and its high concentration eventually blocks conduction of the C‐fibers. This
results in long‐lasting sensory deficits. These properties give a logical basis for the use of
capsaicin in treating pains that arise from cluster headache, complex regional pain syndrome,
postmastectomy pain, postherpetic neuralgia, and diabetic neuropathy [16, 37, 38].
In his review, Caterina et al. [39] had shown that capsaicin has an expression‐cloning strategy
based on calcium influx to isolate a functional cDNA encoding of a capsaicin receptor from
sensory neurons. Capsaicin receptor is a nonselective cation channel that is structurally related
to members of the transient‐receptor‐potential V1 (TRPV1) family of ion channels [36, 40, 41].
The cloned‐capsaicin receptor is also activated by increases in temperature in the noxious
range, which suggests that it acts as a transducer of painful thermal stimuli in vivo.
In all, 28 mammalian transient receptor potential (TRP) cation channels have been identified
and regrouped into six subfamilies [42]. These include TRPC (“canonical”), TRPV (“vanil‐
loid”), TRPM (“melastatin”), TRPP (“polycystin”), TRPML (“mucolipin”), and TRPA (“ankyr‐
in”). The TRPV subfamily (vanilloid receptors) comprises channels critically involved in
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nociception and thermo sensing. Moreover, the TRPV 1 receptors have been found in the brain,
spinal cord, peripheral neurons, smooth and cardiac muscles, vascular tissues, bronchial
muscles, GIT mucosa, and the urinary bladder.
The mechanism of action of capsaicin is based on neuronal desensitization to noxious stimuli.
Two forms of desensitization are apparent. One is a capsaicin‐induced loss of responsiveness.
This is functional and it is reversible. On the other hand is a calcium‐dependent desensitization
involving the activation of phosphatase and leading to the inactivation of capsaicin channel.
High doses of capsaicin may lead to neurotoxicity. Axonal and terminal degeneration and
impaired nociception appear to be irreversible. Both osmotic lysis and action of calcium‐
dependent proteases may be responsible for capsaicin‐induced neurotoxicity [43–47].
In acute pain, studies in animals have shown that systemic capsaicin relieves pain in increasing
doses from 0.5 to 10 mg/kg, but nerve degeneration was noted in doses of 50 mg/kg and greater.
The relief was for mechano‐thermal pain [48–51]. In human studies, it requires days to weeks
before beneficial effects of capsaicin can be seen [52].
With an increase in the levels of substance P in inflammatory and neurogenic joint diseases
(arthritis), topical or intra‐articular injections of capsaicin have shown significant improve‐
ments, as well as reductions in the level of inflammatory mediators [53–57]. In the same vein,
Perkins and Campbell [58] used 6 mg/kg of intra‐articular capsaicin to reverse mechanical
hyperalgesia for several hours [59, 60].
In rheumatoid arthritis, the effect of capsaicin is mixed. Whereas Deal et al. [48] showed
significant reduction in the level of pain intensity in 31 patients with rheumatoid arthritis of
the knee following treatment with zostrix (as 0.025%) for 4 weeks, McCarthy and McCarty [62]
did not observe any improvement in 7 patients with rheumatoid hands, using 0.75% capsaicin.
However, Weisman et al. [49, 61, 62] reported that application of capsaicin (0.75%) for 6 weeks
produced a reduction in inflammatory mediators, including substance P, in the synovial fluid
of patients with rheumatoid arthritis. In osteoarthritis, there is evidence to show increase in
the level of substance P in patients, [4, 53]. Randomized, controlled trials have also shown
significant improvement in pain relief following treatment with capsaicin cream [23, 34, 43, 53].
With neuropathic pain in mind, animal studies using intrathecal as well as subcutaneous or
topical capsaicin have produced significant improvements in the relief of hyperalgesia and
pain [37, 63–66, 72]. These studies show that capsaicin‐sensitive nerves have a role in thermal
hyperalgesia in the animals under study [66, 67].
Studies in humans with neuropathic pain include patients with postherpetic neuralgia [51,
68], diabetic neuropathy [69], and postmastectomy pain [44]. Others include the use of
capsaicin in stump or phantom pain [70], complex regional pain syndrome type I [71],
trigeminal neuralgia [72], and oral neuropathic pain [64]. Capsaicin was also studied in cluster
headache, and fibromyalgia [17], as well as in acute or chronic conditions, such as osteoarthri‐
tis [48, 64]; and rheumatoid arthritis [37].
Notable among these studies are those by the Capsaicin Study Group [73] with a total of 277
patients (138 capsaicin 0.075%, 139 placebo) having diabetic neuropathy. The Group reported
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significant improvements in all measures (pain, walking, working, and sleeping) after
administering capsaicin four times daily for up to 8 weeks. In their study, Jensen and Larson
[74] found that capsaicin cream provides an alternative treatment option with a favorable
outcome in painful diabetic neuropathy. Most of these studies were performed over similar
periods of time, except the study by Watson et al. [75], which followed up 83 patients with
postherpetic neuralgia for 2 years. The investigators found that in 86% of their patients,
improvements in the pain scores were either maintained or further enhanced with no serious
side effects. Furthermore, the efficacy of nasal application of capsaicin in the treatment of
cluster headache had been confirmed following 7 days application of capsaicin with significant
improvement when compared with placebo. The relief might have been produced through the
effects of capsaicin on substance P–containing trigeminal nerve [76, 77].
Capsaicin has also been shown to relief pruritus in patients with psoriasis [28, 70, 78], bra‐
chioradial pruritus [79], aquagenic pruritus [80], notalgia parasthetica [24], nodular prurigo
[79], and pruritus produced in patients on hemodialysis [81]. In human volunteers, capsaicin
treatment was found to have inhibited itch after histamine and allergen challenge. Itch is
mediated by a subset of capsaicin‐sensitive nociceptive neurons through the inhibition of C
fiber conduction [82, 83].
The wide systemic side effects have made topical capsaicin to be more acceptable in clinical
state. The main side effects are neuronal, cardiovascular, mucocutaneous tissue, or open
wounds. Electron microscopic observations have revealed degeneration and glial engulfment
of buttons and unmyelinated axons in the dorsal horn, 2–6 hours after neonatal subcutaneous
capsaicin injections in rats. There is increased latency of the nerves; convulsion and even death
may follow with very high doses of capsaicin [84, 85]. Cannabinoids have been used to
attenuate capsaicin‐evoked hyperalgesia [78] and low‐dose lidocaine was found to reduce
capsaicin‐evoked secondary analgesia by a central mechanism [34].
When capsaicin is in contact with mucocutaneous tissues, such as the conjunctiva, it produces
intense inflammatory reaction [86]. This is consequent upon the initial release of substance
P. Cardiovascular studies on blood vessels have shown that both capsaicinoids and capsaicin
could inhibit vasoconstriction induced by norepinephrine [17], and the vasodilatation effect
of capsaicinoids might be due to the action of capsaicin. The compounds also cause signifi‐
cant decreases in platelet aggregation induced by ADP and collagen and increase blood flow
in volunteers. During their study in Thailand, Jaiarj et al. [67] first noticed that people who
consume large amounts of red chili peppers experienced a lower incidence of thromboemb‐
olism, or potentially dangerous blood clots.
The alternative to the mixed actions of capsaicin is being looked into through the development
of purer and more potent capsaicin analogs. Refs. [72, 79, 80, 62] reported significant thermal
and mechanical analgesia and antiinflammatory activity following administration of olvanil
oleamide, an analog, which lacked the acute toxicity of capsaicin. Nuvanil was found to be
more soluble, thus allowing for oral administration, and also showed improved oral activity
and significant analgesia [6,87]. The compounds were also found to show less pungency and
reduced vagal‐mediated blood pressure reflexes [6,79, 80, 83, 87]. In this regard, Lee et al. [88]
and Lee and Gauci [27] discussed how acute toxicity of capsaicin can be prevented through
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structural modification. Moreover, Chen et al. [89] and Hua et al. [90] also reported that orally
active capsaicin analog, civamide, showed a significant increase in response latency on the
thermal withdrawal test that persisted for 3 days in adult rats.
5. Conclusion
From the synopsis above, it is obvious that capsaicin is a peripheral analgesic, which is cell
specific. The opening of capsaicin‐operated channels is required for efficacy and agonism.
Improvement in the therapeutic window is required before the use of an orally active thera‐
peutic drug. However, topical applications of capsaicin have been shown to be effective
without side effect [34, 37]. There is also a growing body of evidence for the role of capsaicin
in inflammation, coagulation, and gastro‐intestinal function.
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